Potency and spectrum of garenoxacin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999-2004)

Diagnostic Microbiology and Infectious Disease

Volumn 58, Issue 1, 2007, Pages 19-26

  Fritsche, Thomas R ^a   Sader, Helio S ^a   Jones, Ronald N ^a,b  

^a JMI LABORATORIES   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Fluoroquinolones; Garenoxacin; Skin and soft tissue infections

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CEFEPIME; CEFOXITIN; CEFTAZIDIME; CEFTRIAXONE; CHLORAMPHENICOL; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN; ERYTHROMYCIN; GARENOXACIN; GATIFLOXACIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; OXACILLIN; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN B; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINUPRISTIN; TEICOPLANIN; TETRACYCLINE; VANCOMYCIN;

ACINETOBACTER; ALPHA HEMOLYTIC STREPTOCOCCUS; ARTICLE; BACTERIUM ISOLATION; BETA HEMOLYTIC STREPTOCOCCUS; DRUG ACTIVITY; DRUG POTENCY; ENTEROBACTER AEROGENES; ENTEROCOCCUS; ESCHERICHIA COLI; EUROPE; GRAM NEGATIVE INFECTION; GRAM POSITIVE BACTERIUM; HEALTH CENTER; HEALTH PROGRAM; HOSPITAL INFECTION; HUMAN; IN VITRO STUDY; KLEBSIELLA; METHODOLOGY; MINIMUM INHIBITORY CONCENTRATION; NORTH AMERICA; PRIORITY JOURNAL; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; SKIN INFECTION; SOFT TISSUE INFECTION; SOUTH AND CENTRAL AMERICA; STAPHYLOCOCCUS AUREUS;

ADULT; ANTI-BACTERIAL AGENTS; ASIA; EUROPE; FEMALE; FLUOROQUINOLONES; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; LATIN AMERICA; MALE; MICROBIAL SENSITIVITY TESTS; NORTH AMERICA; PACIFIC OCEAN; POPULATION SURVEILLANCE; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS;

EID: 34247884537     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2006.12.009     Document Type: Article

References (39)

1. Andes D., and Craig W.A. Pharmacodynamics of the new des-f(6)-quinolone garenoxacin in a murine thigh infection model. Antimicrob. Agents Chemother. 47 (2003) 3935-3941
2. Andrade S.S., Jones R.N., Gales A.C., and Sader H.S. Increasing prevalence of antimicrobial resistance among Pseudomonas aeruginosa isolates in Latin American medical centres: 5 year report of the SENTRY Antimicrobial Surveillance Program (1997-2001). J. Antimicrob. Chemother. 52 (2003) 140-141
3. Andrews J., Honeybourne D., Jevons G., Boyce M., Wise R., Bello A., and Gajjar D. Concentrations of garenoxacin in plasma, bronchial mucosa, alveolar macrophages and epithelial lining fluid following a single oral 600 mg dose in healthy adult subjects. J. Antimicrob. Chemother. 51 (2003) 727-730
4. Ariza H., Jasovich A., Fuentes C., and Waskin H. Sequential IV to PO garenoxacin vs. IV ampicillin/sulbactam to amoxicillin/clavulanate to treat serious acute pelvic infection. 45th ICAAC, Washington, DC (2005) (Abstr. L-2236)
5. Buck J.M., Como-Sabetti K., Harriman K.H., Danila R.N., Boxrud D.J., Glennen A., and Lynfield R. Community-associated methicillin-resistant Staphylococcus aureus, Minnesota, 2000-2003. Emerg. Infect. Dis. 11 (2005) 1532-1538
6. Clinical and Laboratory Standards Institute. Approved Standard M7-A7: Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. 7th ed. (2006), NCCLS, Wayne, PA
7. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing, 16th Informational Supplement M100-S16 (2006), NCCLS, Wayne, PA
8. Donati M., Pollini G.M., Sparacino M., Fortugno M.T., Laghi E., and Cevenini R. Comparative in vitro activity of garenoxacin against Chlamydia spp. J. Antimicrob. Chemother. 50 (2002) 407-410
9. Eron L.J., Lipsky B.A., Low D.E., Nathwani D., Tice A.D., and Volturo G.A. Managing skin and soft tissue infections: expert panel recommendations on key decision points. J. Antimicrob. Chemother. 52 Suppl 1 (2003) i3-i17
10. Fluit A.C., Schmitz F.J., and Verhoef J. Frequency of isolation of pathogens from bloodstream, nosocomial pneumonia, skin and soft tissue, and urinary tract infections occurring in European patients. Eur. J. Clin. Microbiol. Infect. Dis. 20 (2001) 188-191
11. Frazee B.W., Salz T.O., Lambert L., and Perdreau-Remington F. Fatal community-associated methicillin-resistant Staphylococcus aureus pneumonia in an immunocompetent young adult. Ann. Emerg. Med. 46 (2005) 401-404
12. Free T., Dewan M., Fogarty C., and Weclaw C. Double-Blind Randomized Oral Garenoxacin vs. Azithromycin in the Treatment of Acute Exacerbation of Chronic Bronchitis. 45th ICAAC, Washington, DC (2005) (Abstr. L-563)
13. Fritsche T.R., Sader H.S., Stilwell M.G., Dowzicky M.J., and Jones R.N. Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004). Diagn. Microbiol. Infect. Dis. 52 (2005) 195-201
14. Fung H.B., Chang J.Y., and Kuczynski S. A practical guide to the treatment of complicated skin and soft tissue infections. Drugs 63 (2003) 1459-1480
15. Fung-Tomc J.C., Minassian B., Kolek B., Huczko E., Aleksunes L., Stickle T., Washo T., Gradelski E., Valera L., and Bonner D.P. Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756. Antimicrob. Agents Chemother. 44 (2000) 3351-3356
16. Goossens H. European status of resistance in nosocomial infections. Chemotherapy 51 (2005) 177-181
17. Gordon K.A., Pfaller M.A., and Jones R.N. BMS284756 (formerly T-3811, a des-fluoroquinolone) potency and spectrum tested against over 10,000 bacterial bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Programme (2000). J. Antimicrob. Chemother. 49 (2002) 851-855
18. Hecht D.W., and Osmolski J.R. Activities of garenoxacin (BMS-284756) and other agents against anaerobic clinical isolates. Antimicrob. Agents Chemother. 47 (2003) 910-916
19. Higa F., Akamine M., Haranaga S., Tohyama M., Shinzato T., Tateyama M., Koide M., Saito A., and Fujita J. In vitro activity of pazufloxacin, tosufloxacin and other quinolones against Legionella species. J. Antimicrob. Chemother. 56 (2005) 1053-1057
20. Ince D., Zhang X., Silver L.C., and Hooper D.C. Dual targeting of DNA gyrase and topoisomerase IV: target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone. Antimicrob. Agents Chemother. 46 (2002) 3370-3380
21. Jones R.N. Global epidemiology of antimicrobial resistance among community-acquired and nosocomial pathogens: a five-year summary from the SENTRY Antimicrobial Surveillance Program (1997-2001). Semin. Respir. Crit. Care Med. 24 (2003) 121-134
22. Kirby J.T., Mutnick A.H., Jones R.N., Biedenbach D.J., and Pfaller M.A. Geographic variations in garenoxacin (BMS284756) activity tested against pathogens associated with skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (2000). Diagn. Microbiol. Infect. Dis. 43 (2002) 303-309
23. Kowalski T.J., Berbari E.F., and Osmon D.R. Epidemiology, treatment, and prevention of community-acquired methicillin-resistant Staphylococcus aureus infections. Mayo Clin. Proc. 80 (2005) 1201-1207 (quiz 1208)
24. Krievins D., Akers D., Joasovich A., Siami G., and Waskin H. Once-daily garenoxacin IV to PO vs. QID piperacillin/tazobactam IV to TID amoxicillin/clavulanate PO for the treatment of complicated skin infections. 45th ICAAC, Washington, DC (2005) (Abstr. L-560)
25. Lee S.Y., Kuti J.L., and Nicolau D.P. Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance. Surg. Infect. (Larchmt) 6 (2005) 283-295
26. Liebetrau A., Rodloff A.C., Behra-Miellet J., and Dubreuil L. In vitro activities of a new des-fluoro(6) quinolone, garenoxacin, against clinical anaerobic bacteria. Antimicrob. Agents Chemother. 47 (2003) 3667-3671
27. Lister P.D. Impact of AUC/MIC ratios on the pharmacodynamics of the des-F(6) quinolone garenoxacin (BMS-284756) is similar to other fluoroquinolones. J. Antimicrob. Chemother. 51 (2003) 199-202
28. Lopez Sisniega J., Tlili N., Sher L., and Weclaw C. Double-Blind, Randomized Garenoxacin vs. Amoxicillin/Clavulanate in the Treatment of Acute Bacterial Sinusitis. 45th ICAAC, Washington, DC (2005) Abstr. L-561
29. Mongkolrattanothai K., and Daum R.S. Impact of community-associated, methicillin-resistant Staphylococcus aureus on management of the skin and soft tissue infections in children. Curr. Infect. Dis. Rep. 7 (2005) 381-389
30. Nathwani D. Tigecycline: clinical evidence and formulary positioning. Int. J. Antimicrob. Agents 25 (2005) 185-192
31. Pereyre S., Renaudin H., Bebear C., and Bebear C.M. In vitro activities of the newer quinolones garenoxacin, gatifloxacin, and gemifloxacin against human mycoplasmas. Antimicrob. Agents Chemother. 48 (2004) 3165-3168
32. Rennie R.P., Jones R.N., and Mutnick A.H. Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 2000). Diagn. Microbiol. Infect. Dis. 45 (2003) 287-293
33. Roblin P.M., Reznik T., and Hammerschlag M.R. In vitro activity of garenoxacin against recent clinical isolates of Chlamydia pneumoniae. Int. J. Antimicrob. Agents 21 (2003) 578-580
34. Sader H.S., Jones R.N., and Silva J.B. Skin and soft tissue infections in Latin American medical centers: four-year assessment of the pathogen frequency and antimicrobial susceptibility patterns. Diagn. Microbiol. Infect. Dis. 44 (2002) 281-288
35. Schmitz F.J., Boos M., Mayer S., Jagusch H., and Fluit A.C. Increased in vitro activity of the novel des-fluoro(6) quinolone BMS-284756 against genetically defined clinical isolates of Staphylococcus aureus. J. Antimicrob. Chemother. 49 (2002) 283-287
36. Schmitz F.J., Boos M., Mayer S., Kohrer K., Scheuring S., and Fluit A.C. In vitro activities of novel des-fluoro(6) quinolone BMS-284756 against mutants of Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus selected with different quinolones. Antimicrob. Agents Chemother. 46 (2002) 934-935
37. Schmitz F.J., Milatovic D., Boos M., Mayer S., and Fluit A.C. In vitro activity of the novel des-F(6) quinolone BMS-284756 against genetically characterized clinical streptococcal isolates, including isolates with reduced quinolone susceptibility. J. Antimicrob. Chemother. 49 (2002) 698-701
38. Stevens D.L., Bisno A.L., Chambers H.F., Everett E.D., Dellinger P., Goldstein E.J., Gorbach S.L., Hirschmann J.V., Kaplan E.L., Montoya J.G., and Wade J.C. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin. Infect. Dis. 41 (2005) 1373-1406
39. Tellier G., Sullivan J., Fogarty C., and Giordano P. Double-blind, randomized 5-day garenoxacin vs. 7- to 10-day clarithromycin to treat community-acquired pneumonia. 45th ICAAC, Washington, DC (2005) (Abstr. L-567)